Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05CFG
|
|||
| Former ID |
DNCL002556
|
|||
| Drug Name |
PR104
|
|||
| Synonyms |
851627-62-8; PR-104; PR104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5- dinitro-N-(2-(phosphonooxy)ethyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | |
| Company |
Proacta
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H20BrN4O12PS
|
|||
| Canonical SMILES |
CS(=O)(=O)OCCN(CCBr)C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C(=O)NCCOP(=O)(O)O
|
|||
| InChI |
1S/C14H20BrN4O12PS/c1-33(28,29)31-7-5-17(4-2-15)13-11(14(20)16-3-6-30-32(25,26)27)8-10(18(21)22)9-12(13)19(23)24/h8-9H,2-7H2,1H3,(H,16,20)(H2,25,26,27)
|
|||
| InChIKey |
GZSOKPMDWVRVMG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 851627-62-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00544674) PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.